Pulmonary Disease, Chronic Obstructive: Clinical Trials

355 trials for Pulmonary Disease, Chronic Obstructive, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

275 completed, 21 terminated, 18 recruiting, 18 unknown. 355 Phase 1, 65 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1355Completed 275, Terminated 21, Recruiting 18, Unknown 18, Withdrawn 9, Not yet recruiting 7, Active not recruiting 4, Suspended 3
Phase 265Completed 34, Recruiting 8, Unknown 8, Terminated 5, Withdrawn 5, Not yet recruiting 3, Suspended 2

Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive

Trials (filtered) newest first · largest first

All 355 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
cfMSC Stem Cell Therapy Targeting COPD
clonal fetal MSCs - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-11-02
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
Metformin - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1Not yet recruitingDuke University452027-02-012026-11-03
The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD
Inhaled Nitric Oxide, Placebo - Chronic Obstructive Pulmonary Disease
Phase 1 / Phase 2Not yet recruitingUniversity of Alberta802026-12-012026-07-08
A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment
RSS0343 Tablet - Non-cystic Fibrosis Bronchiectasis, Chronic Sinusitis Without Nasal Polyps
Phase 1Not yet recruitingReistone Biopharma Company Limited242026-11-012026-11-17
A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RO7830698, Placebo - Chronic Obstructive Pulmonary Disease (COPD), Healthy Participants
Phase 1 / Phase 2RecruitingHoffmann-La Roche1042026-10-282026-11-13
A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease
Stem cells - Chronic Obstructive Lung Disease
Phase 1 / Phase 2Not yet recruitingSMSbiotech1252026-10-012026-10-13
Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients
AERO-002 (60 mcg), Glycopyrrolate (18 mcg) - COPD (Chronic Obstructive Pulmonary Disease)
Phase 1CompletedAeroRx Therapeutics Inc.242026-09-212026-10-15
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
R-3750 - COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation
Phase 1Not yet recruitingRise Therapeutics LLC272026-09-012026-01-29
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants
GSK3862995B - Pulmonary Disease, Chronic Obstructive
Phase 1RecruitingGlaxoSmithKline242026-08-182026-09-01
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD
KIT2014, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1 / Phase 2RecruitingKither Biotech Srl362026-08-052026-10-20
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD
HRS-9821 Powder for Inhalation, Placebo - COPD
Phase 1RecruitingGuangdong Hengrui Pharmaceutical Co., Ltd482026-07-092026-07-20
Impact of Eradication Therapy on Helicobacter Pylori Infection With Chronic Obstructive Pulmonary Disease:
Eradication of Helcobacter Pylori - Chronic Obstructive Pulmonary Disease (COPD), With Poitive H Pylori
Phase 1RecruitingZagazig University542026-03-012026-11-05
Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease
RB042, Placebo inhalation solution - Healthy, Healthy Smoker
Phase 1RecruitingAtisama Therapeutics1052026-02-162026-08-12
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray - Chronic Obstructive Pulmonary Disease
Phase 1TerminatedChia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.332025-11-252026-08-27
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
BBT002, Placebo - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1RecruitingBambusa Therapeutics682025-09-052026-07-22
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension, HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placebo, Moxifloxacin Hydrochloride Tablets - COPD
Phase 1CompletedGuangdong Hengrui Pharmaceutical Co., Ltd852025-08-112026-09-09
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations
XH-S004 20 mg, 40 mg or 60 mg, Placebo - Chronic Obstructive Pulmonary Disease
Phase 1Active not recruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.812025-07-152026-09-25
Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).
Stem cells - Chronic Obstructive Lung Disease
Phase 1RecruitingSMSbiotech182025-06-132026-08-11
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
GSK3862995B, Placebo - Pulmonary Disease, Chronic Obstructive
Phase 1CompletedGlaxoSmithKline302025-05-202026-06-11
A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)
BBT002, Placebo - Chronic Obstructive Pulmonary Disease
Phase 1RecruitingBambusa Therapeutics2862025-05-082026-07-01

Showing 20 of 355. Sign in to see all of them.

Narrower conditions

Asthma (45)  ·  Emphysema (18)  ·  Lung Diseases (14)  ·  Respiratory Aspiration (11)  ·  Pulmonary Emphysema (8)  ·  Respiration Disorders (7)  ·  Cystic Fibrosis (6)  ·  Heart Failure (5)  ·  Hypertension, Pulmonary (5)  ·  Inflammation (5)  ·  Dyspnea (4)  ·  Motor Activity (4)  ·  Renal Insufficiency (4)  ·  Bronchitis, Chronic (3)

Broader conditions

Chronic Disease (355)  ·  Disease Attributes (355)  ·  Pathological Conditions, Signs and Symptoms (355)  ·  Pathologic Processes (353)  ·  Lung Diseases, Obstructive (352)  ·  Respiratory Tract Diseases (352)  ·  Lung Diseases (341)  ·  Bronchial Diseases (50)  ·  Immune System Diseases (50)  ·  Hypersensitivity (46)  ·  Hypersensitivity, Immediate (45)  ·  Respiratory Hypersensitivity (45)  ·  Respiration Disorders (20)  ·  Cardiovascular Diseases (11)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)

Interventions

Tiotropium Bromide (14)  ·  Budesonide (11)  ·  Glycopyrrolate (11)  ·  Inhalation (8)  ·  Formoterol Fumarate (7)  ·  GSK573719 (7)  ·  Fluticasone (6)  ·  Moxifloxacin (6)  ·  Albuterol (5)  ·  danirixin (5)  ·  olodaterol (5)  ·  Beclomethasone (4)  ·  Charcoal (4)  ·  Ciprofloxacin (4)  ·  Itraconazole (4)

Sponsors

GlaxoSmithKline (84)  ·  AstraZeneca (32)  ·  Chiesi Farmaceutici S.p.A. (25)  ·  Pearl Therapeutics, Inc. (8)  ·  Boehringer Ingelheim (7)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (6)  ·  Novartis (6)  ·  Pfizer (6)  ·  Aeris Therapeutics (5)  ·  Bayer (5)  ·  Intech Biopharm Ltd. (5)  ·  Pulmatrix Inc. (4)  ·  Theravance Biopharma (4)  ·  Guangdong Hengrui Pharmaceutical Co., Ltd (3)  ·  Hal C Charles (3)

Countries

United States (103)  ·  United Kingdom (96)  ·  Germany (43)  ·  China (30)  ·  Australia (20)  ·  Belgium (11)  ·  New Zealand (8)  ·  Japan (7)  ·  France (6)  ·  Netherlands (6)  ·  Austria (5)  ·  Brazil (5)  ·  Sweden (5)  ·  Taiwan (5)  ·  Bulgaria (4)

Top investigators

Dave Singh, MD (4)  ·  Stuart Mair, MD (4)  ·  Cecil Charles, PhD (3)  ·  Chadwick Orevillo (3)  ·  Carin Jorup (2)  ·  Christian M Kaehler, MD (2)  ·  Colin Reisner, M.D. (2)  ·  Emma Harrop (2)

Results publications

PMID 22793945, PMID 33152467, PMID 16235359, PMID 16565429, PMID 16636091, PMID 16690673, PMID 17132052, PMID 17507545, PMID 18073405, PMID 21975749, PMID 22314182, PMID 22793939, PMID 23074435, PMID 23076942, PMID 23235687, PMID 23256721, PMID 23364286, PMID 2337756, PMID 23992090, PMID 24563632, PMID 24615270, PMID 25450456, PMID 26092545, PMID 26372465, PMID 26372467, PMID 26620151, PMID 29149867, PMID 30425469, PMID 32071044, PMID 32907575, PMID 40391696, PMID 41677208, PMID 12493340, PMID 12543832, PMID 16611654, PMID 19164344, PMID 19436683, PMID 19643947, PMID 19750190, PMID 19880675, PMID 20920189, PMID 20979675, PMID 21311694, PMID 21474911, PMID 21615886, PMID 21852337, PMID 22075481, PMID 22374920, PMID 22465313, PMID 22760901

NIH funding

2015 (7), 2017 (5), 2023 (5), 2008 (3), 2018 (3), 2009 (2), 2014 (2), 2016 (2), 2019 (1), K76AG095138 (1), R01HL096471 (1), R01NR008938 (1), R01NR012009 (1), R03NR009361 (1), R21AT007357 (1)